Xeris Biopharma Holdings, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Xeris Biopharma Holdings announces its 2026 Annual Meeting of Stockholders to be held virtually on June 4, 2026, with key proposals including director elections and auditor ratification.
NASDAQ
Xeris Biopharma Holdings, Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
DEF: Xeris Biopharma Holdings Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals
Xeris Biopharma Holdings will hold its 2025 Annual Meeting of Stockholders virtually on June 4, 2025, to elect directors, ratify the appointment of Ernst & Young LLP, and approve executive compensation.
NASDAQ
Xeris Biopharma Holdings, Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
Xeris Biopharma Holdings is holding its 2024 Annual Meeting of Stockholders to vote on key proposals including the election of directors, ratification of the auditor, executive compensation, and an amendment to the Employee Stock Purchase Plan.